Blood typing has become a routine test item of clinical blood transfusion department and clinical laboratory, which includes ABO blood group, Rh blood group, and cross-matching of blood test.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Digital health technology firm Cue Health is seeking up to $100 million in a proposed initial public offering, it said in a registration statement filed on Wednesday with the US Securities and Exchange Commission.

Belgian molecular diagnostics maker Biocartis on Thursday reported a 31 percent year-over-year increase in revenues for the first half of 2021 on strong sales of its Idylla system and related test cartridges.

August 20, the Hurun Research Institute in association with Jiaxing City released the 2021 Hurun Global 500.

BioMérieux reported sales growth of 7 percent for the first half of 2021.The Marcy l'Etoile, France-based diagnostics firm reported total sales of €1.57 billion ($1.86 billion) for the six-month period ended June 30, 2020, up from €1.48 billion for the first half of 2020.

Seegene said Wednesday that it has obtained CE marking for the use of its Combo Swab self-collection device with four of the firm's SARS-CoV-2 molecular diagnostic assays, enabling its use in the EU and other regions that accept the designation.

As of the end of August 2021, the first-half reports of IVD-related listed companies have basically been released. 64 IVD-related listed companies have achieved steady growth in the first half of 2021, and more than 70% of companies have shown positive growth in net profits.

Companies that have already registered their devices in the EU will still be able to sell their products in Great Britain until June 2023. From this point, they will be required to register their device for UK Conformity Assessed (UKCA) marking.

The second quarter revenues of Burning Rock Biotech were up 19 percent year over year. The Chinese precision oncology firm recorded total revenues of RMB 127.3 million ($19.7 million) for the three months ended June 30, 2021, up from RMB 107 million for the same period in 2020.

The US Food and Drug Administration has granted 510(k) clearance and a CLIA waiver to a multiplex assay from Visby Medical to detect Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis. The assay uses an instrument-free, single-use PCR device.

On August 17th, Autobio released a semi-annual performance report stating that the operating income was 1.678 billion yuan, an increase of 39.13% year-on-year; the net profit attributable to shareholders of listed companies was 413 million yuan, an increase of 50.63% year-on-year.